A forum for researchers, students and applicants in the field of cyclodextrin technology
Rutin (RTN) is a natural flavonoid with well-documented anti-angiogenic, antioxidant, anti-inflammatory, and anti-cancer properties. However, its therapeutic potential is limited
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and
Methyl salicylate (MeSA), a known defense modulator, holds promise as a biostimulant; however, its volatility and poor aqueous solubility limit
Cyclodextrin-based supramolecular polymers (SPCDs) have emerged as promising platforms for cancer therapy via the utilization of cyclodextrin (CD)-mediated host-guest interactions
Rutin (RTN) is a natural flavonoid with well-documented anti-angiogenic, antioxidant, anti-inflammatory, and anti-cancer properties. However, its therapeutic potential is limited
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and
Methyl salicylate (MeSA), a known defense modulator, holds promise as a biostimulant; however, its volatility and poor aqueous solubility limit
This review critically examines how cyclodextrins modulate regulated cell death pathways and the implications for immunometabolism and therapeutic translation. Increasing
The Nanotechnology World Conference (NTWC 2026) will be held on October 18-20, 2026 at Bangkok, Thailand. This year, the conference
It is always exciting to see cyclodextrins moving beyond their traditional roles as solubilizers or carriers and entering the realm
Rainy walks, swims in the lake, or unexpected puddle jumps often leave a dog with that unmistakable “wet dog” smell.
This paper provides a comprehensive review of the research progress on cyclodextrin and polycarbonate in epoxi resin matrix materials. Specifically,
HPβCD has also been investigated as an active pharmaceutical ingredient (API) for the prospective treatment of ischemic stroke. We previously
